Is improvement in the quality of life after subthalamic nucleus stimulation in Parkinson's disease predictable?

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) significantly improves quality of life (QoL) in PD. However, QoL fails to improve in a relevant proportion of patients. We studied clinical baseline and progression parameters associated with improvement in QoL after DBS. Data from a Germ...

Full description

Saved in:
Bibliographic Details
Published in:Movement disorders Vol. 26; no. 14; pp. 2516 - 2521
Main Authors: Daniels, Christine, Krack, Paul, Volkmann, Jens, Raethjen, Jan, Pinsker, Markus O., Kloss, Manja, Tronnier, Volker, Schnitzler, Alfons, Wojtecki, Lars, Bötzel, Kai, Danek, Adrian, Hilker, Rüdiger, Sturm, Volker, Kupsch, Andreas, Karner, Elfriede, Deuschl, Günther, Witt, Karsten
Format: Journal Article
Language:English
Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01-12-2011
Wiley
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Deep brain stimulation (DBS) of the subthalamic nucleus (STN) significantly improves quality of life (QoL) in PD. However, QoL fails to improve in a relevant proportion of patients. We studied clinical baseline and progression parameters associated with improvement in QoL after DBS. Data from a German randomized, controlled study comparing DBS (60 patients) with best medical treatment (59 patients) were analyzed. Changes in patients' QoL were assessed using the Parkinson's Disease Questionnaire (PDQ‐39) at baseline and at the 6‐month follow‐up. For the STN‐DBS patients, the changes in PDQ‐39 were correlated with predefined clinical preoperative and progression parameters. Scores for QoL improved after STN‐DBS for 57% of the patients, and for 43% patients, they did not improve. Patients with improvement in QoL showed significantly higher cumulative daily “off” time. Changes in the PDQ‐39 showed a significant positive correlation with the cumulative daily off time at baseline. Logistic regression analysis revealed that 1 additional hour off time at baseline increases the odds for improvement on PDQ‐39 by a factor of 1.33 (odds ratio). In the postoperative course, changes in the PDQ‐39 significantly correlated with the reduction of cumulative daily off time, an improvement on the UPDRS (UPDRS III off), and positive mood changes. Among the baseline parameters, the cumulative daily off time is the strongest predictor for improvement in disease‐related QoL after DBS. Improvement in QoL after STN‐DBS is also correlated with changes in motor functions and changes in depression and anxiety. © 2011 Movement Disorder Society
Bibliography:Funding agencies: This study was supported by the Parkinson Foundation Europe and the German Ministry of Research and Technology (01GI0201) Kompetenznetz Parkinson, TP3.
Full financial disclosures and author roles may be found in the online version of this article.
ArticleID:MDS23907
Relevant conflicts of interest/financial disclosures: Drs. Bötzel, Deuschl, Krack, Krause, Kupsch, Pinsker, Schnitzler, Sturm, Tronnier, Volkmann, and Wojtecki report having received speaking fees from Medtronic; Drs. Deuschl, Tronnier, Volkmann, and Wojtecki report having received consulting fees from Medtronic; Drs. Deuschl, Kupsch, Krause, Krack, and Volkmann report having received research grants from Medtronic; and Dr. Sturm reports owning stock options from Medtronic. No other potential conflict of interest relevant to this article was reported.
istex:A5E7E464341E6A4CAE24AA74AABD71E1210FB514
ark:/67375/WNG-N3PT6NLL-R
This study was supported by the Parkinson Foundation Europe and the German Ministry of Research and Technology (01GI0201) Kompetenznetz Parkinson, TP3.
Drs. Bötzel, Deuschl, Krack, Krause, Kupsch, Pinsker, Schnitzler, Sturm, Tronnier, Volkmann, and Wojtecki report having received speaking fees from Medtronic; Drs. Deuschl, Tronnier, Volkmann, and Wojtecki report having received consulting fees from Medtronic; Drs. Deuschl, Kupsch, Krause, Krack, and Volkmann report having received research grants from Medtronic; and Dr. Sturm reports owning stock options from Medtronic. No other potential conflict of interest relevant to this article was reported.
Relevant conflicts of interest/financial disclosures
Funding agencies
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
ISSN:0885-3185
1531-8257
DOI:10.1002/mds.23907